Newsfeed delivered by KI.se
News from KI
Tuesday September 19th, 2017 01:07:10 PM
KIB will perform some system maintenance on friday 22/9 on kib.ki.se
This will happen between 17:00-22:00 and the webpage will be unreachable under some of that time.
There will be, when its possible a redirect to a system maintenance page, where most of the info/links from kib.ki.se will be.
Tuesday September 19th, 2017 09:10:13 AM
By reprogramming skin cells into nerve cells, researchers at Karolinska Institutet are creating cell models of the human brain. In a new study published in Molecular Psychiatry the researchers describe how cells from patients with the severe developmental disease lissencephaly differ from healthy cells. The method can provide vital new knowledge on difficult-to-study congenital diseases.
Lissencephaly is a rare congenital developmental disease that can be caused by, amongst other anomalies, a mutation of the DCX gene. Affected individuals are born with serious developmental disabilities and a brain that is smooth instead of folded.
Uses award-winning technique
The discovery that it is possible to reprogramme specialised cells such as skin cells in order to reverse their development back to stem cells was rewarded with the 2012 Nobel Prize. The resulting so-called iPS-cells (induced pluripotent stem cells) can then be turned into other specialised cell types.
Anna Falk, docent at Karolinska Institutet’s Department of Neuroscience, uses this technique to build cell models of the human brain. In the present study, her team took skin cells from patients with lissencephaly and turned them into iPS cells, which they then cultivated under special conditions into neuronal stem cells and neurons that are copies of those in the patients’ brains.
By examining the cell cultivation dishes, the researchers were able to observe how the patients’ cells behaved and developed from stem cells to nerve cells and compare them with cells from healthy controls. They found that the diseased cells matured much more slowly, sent out shorter projections and were much less mobile.
“It’s already known that DCX affects the ability of neurons to migrate, but we can now show that DCX plays a much greater, broader part in brain development than that,” says Dr Falk. “Our hypothesis is that it’s this, the damaged nerve cells’ resistance to maturation that causes the disease.”
No relevant animal models
Since there are no relevant animal models for lissencephaly, the reprogramming technique has been essential to the study of lissencephaly’s underlying pathogenesis. At Dr Falk’s laboratory, the method is used to also study other congenital diseases that affect the brain, such as autism and Down syndrome. In future projects, the researchers hope to study how diseased cells can be modified to act as healthy cells.
“What many developmental diseases have in common seems to be the failure of brain cells to mature at the same rate as they do in healthy people,” says Dr Falk. “Trying to influence the cells so that they behave like healthy cells is the first step towards some kind of therapy for these diseases.”
The study was a collaboration with Karolinska University Hospital, Uppsala University, SciLifeLab and the Salk Institute for Biological Studies in the USA. It was financed by several bodies, including the Swedish Foundation for Strategic Research, the Åke Wiberg Foundation, the Tore Nilson Foundation, the Jeansson Foundations, the Thuring Foundation and the Swedish Research Council, and through the KID and SFO funding schemes.
”An in vitro model of lissencephaly: expanding the role of DCX during neurogenesis”
M Shahsavani, R Pronk, R Falk, M Lam, M Moslem, S Linker, J Salma, K Day, J Schuster, B-M Anderlid, N Dahl, FH Gage, A Falk
Molecular Psychiatry, online 19 September 2017. doi: 10.1038/MP.2017.175
Tuesday September 19th, 2017 07:33:17 AM
Tips from KI Grants Office about current calls
Swedish and Nordic grants
Neuro Association | Neuroförbundet
Stöder medicinskt forsknings- och utvecklingsarbete om neurologiska sjukdomar samt socialt och beteendevetenskapligt forsknings- och utvecklingsarbete inom området.
Closing date: 29 Sep 2017
ERC-2018-PoC proof of concept grants - Horizon 2020: Excellent Science, EU
These aim to maximise the value of ERC-funded research by funding further work to verify the innovation potential of ideas arising from ERC funded projects. The total budget is €20 million to fund an estimated 130 projects. Grants are worth up to €150,000 each over up to 18 months.
Closing date: 16 Jan 2018
Susanne Klein-Vogelbach prize for the research of human movement - Georg and Susanne Klein Vogelbach Foundation
The Georg and Susanne Klein-Vogelbach Foundation invites applications for the Susanne Klein-Vogelbach prize for the research of human movement. This recognises researchers in neuroscience, orthopaedics and associated sciences which is oriented to establish a better understanding of the underlying principles of human movement and its rehabilitation, meaning all kinds of muscular-induced human movement, including mime and music.
Closing date: 10 Oct 2017
Dr HP Heineken prize for biochemistry and biophysics - Royal Netherlands Academy of Arts and Sciences (KNAW) | Koninklijke Nederlandse Akademie van Wetenschappen
The Royal Netherlands Academy of Arts and Sciences (KNAW) invites nominations for the Dr HP Heineken prize for biochemistry and biophysics. This recognises outstanding research in biochemistry and biophysics. Internationally renowned researchers in biochemistry or biophysics whose research still holds considerable promise for future innovative discoveries may be nominated.
Closing date: 15 Oct 2017
The Royal Netherlands Academy of Arts and Sciences (KNAW) invites nominations for the Dr AH Heineken prize for medicine. This recognises pioneering work in medical research. Internationally renowned medical researchers whose research holds promise for future innovative discoveries may be nominated.
Closing date: 15 Oct 2017
JUST-2017-AG-DRUG supporting initiatives in the field of drugs policy - Directorate-General for Justice
The Directorate-General for Justice invites proposals for the JUST-2017-AG-DRUG call supporting initiatives in the field of drugs policy. This call supports projects in the field of drugs policy in regards to judicial cooperation and crime prevention. Priority is given to supporting:
Activities in the area of identification and epidemiology of use of new psychoactive substances;
Activities aimed at the effective response to the challenges posed by the online trade of drugs;
Civil society organisations by reinforcing their advocacy function, capacity to make a difference at the local level, best practice sharing methods and knowledge and skills on evidence-based interventions and minimum quality standards in the field of drug demand reduction;
Key stakeholders in the field of prevention by expanding their knowledge and skills, in particular in the context of minimum quality standards.
Closing date: 15 Oct 2017
Federal Funding agencies
Innovative Approaches or Technologies to Investigate Regional, Structural and Functional Heterogeneity of CNS Small Blood and Lymphatic Vessels (R01) -NIH
This Funding Opportunity Announcement (FOA) will solicit research projects focused on the development of new technology and tools, or novel mechanistic studies, or a combination of mechanistic and technology development studies specific to central nervous system (CNS, which includes retina) small blood and lymphatic vessels in health and disease, across the life span. The program aims at facilitating the development of tools and technology to image, profile and map CNS small blood and lymphatic vessels. Additional goals are to elucidate the mechanisms underlying CNS small blood and lymphatic vessels structural and functional heterogeneity, differential susceptibility to injury, role in disease and repair processes, and their responses to therapies. Preclinical studies using in vitro and/or animal models specific to CNS small blood and lymphatic vessels alone or in combination with pilot human studies are appropriate for this FOA.
Closing dates: Dec11, 2017, by 5:00 PM local time of applicant organization.
Human Studies of Target Identification, Biomarkers and Disease Mechanisms Specific to CNS Small Blood and Lymphatic Vessels (R01) -NIH
This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.
Closing dates: Dec 11, 2017, by 5:00 PM local time of applicant organization.
Angelman syndrome call for proposals — Angelman Syndrome Foundation
The Angelman Syndrome Foundation invites proposals for its research on Angelman syndrome grants. These support research in preclinical, translational and clinical areas that investigate all aspects of Angelman syndrome.
Priority will be given to pilot projects that test new ideas on the pathogenesis and therapy of the syndrome. Studies related to communication, behavioural issues and identification of issues and treatments that impact the daily lives of people with the disease and their families are of particular interest.
Closing dates: Applications due on every Oct 15 and April 15.
Alzheimer's Disease Research Grants— BrightFocus Foundation
The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies.
Closing date: Oct 18, 2017 11:59 p.m. EST (Washington, D.C.)
Career Development Award for Pediatric Cancer Research— American Association for Cancer Research
The American Association for Cancer Research, in partnership with Aflac Inc, invites applications for its career development awards for paediatric cancer research. These support junior faculty in conducting paediatric cancer research and establishing successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to paediatric cancer.
Closing dates: 10/18/2017 1:00:00 PM Eastern Standard Time.
QuadW Foundation-AACR Fellowship for Clinical/Translational Sarcoma Research— American Association for Cancer Research
The American Association for Cancer Research, in partnership with the QuadW Foundation, invites applications for its fellowship for clinical and translational sarcoma research. This supports a postdoctoral or clinical research fellow to conduct translational or clinical sarcoma research and to establish a successful career path in this field.
Closing date: 25 Oct 2017 1:00:00 PM Eastern Standard Time.
Prevention innovative grants— Juvenile Diabetes Research Foundation International
The Juvenile Diabetes Research Foundation International invites applications for its prevention innovative grants. These provide seed funding for innovative research projects with potential to accelerate the mission of the foundation on curing type 1 diabetes. Proposals should address key questions and have the potential to lead to a change in the current paradigm or conventional wisdom or lead to a groundbreaking discovery. Preliminary data is not required in the proposal but the underlying premise, goal, or hypothesis must be plausible and testable and the proposal must be focused with a well defined goal that is achievable within the timeframe of the award.
Closing date: 31 Oct 2017
Research grant programme – idea grants - Barth Syndrome Foundation
The Barth Syndrome Foundation, under the research grant programme, invites proposals for its idea grants. These support basic science and clinical research on the natural history, biochemical basis and treatment of Barth syndrome. Although any research proposal related to Barth syndrome is considered, the following areas are of particular interest:
•mechanism of neutropenia in Barth syndrome;
•gastrointestinal pathophysiology in Barth syndrome;
•search for compounds that may improve mitochondrial performance in Barth syndrome.
Closing date: 31 Oct 2017
Tuesday September 19th, 2017 07:14:15 AM
Since the 2017 autumn term, the two new core facilities “Chemical Proteomics” and “VirusTech”, located at KI’s Department for Medical biochemistry and biophysics, MBB, are available to researchers nationwide.
The Chemical Proteomics facility opened to provide specialized support to KI and other Swedish universities on drug discovery and development, particularly providing proteome-wide identification and characterization of drug targets and/or mechanism of actions. The facility is run by Max Gaetani under Roman Zubarev´s direction and is part of the joint Chemical Proteomics & Proteogenomics SciLifeLab national facility. It is primarily funded by the Swedish national infrastructure for biological mass spectrometry (BioMS).
“Time has arrived to let cells and tissues speak for themselves after drug treatments through their proteome-wide changes which we will use as an opportunity for a much brighter understanding and discovery of drug targets and mechanisms”, says Max Gaetani, head of the facility.
The new facility is also organizing an introductory three day course, from 7 through 9 November 2017, targeted towards PhD students, postdocs and other researchers from Swedish universities. Participants will learn about current advances of MS-based proteomics strategies with aims in drug discovery and development, in particular for proteome-wide identification and characterization of compound-target interactions.
Virus Tech in collaboration with CMB
In addition, MBB’s Jens Hjerling-Leffler has together with Emma Andersson (CMB/BioNut) started the VirusTech Core Facility which is headed by Albert Blanchart Aguado. It specializes in the production and concentration of Lentiviral and Adeno Associated Viruses (AAVs), but it also works with developing and optimizing the production of other types of viruses.
“Viral manipulations allow for relatively cheap, quick and precise manipulation of biological systems ranging from over–expression to gene-knockouts. This is an extremely fast-developing field and there has been an unmet need with regards to capability for high-quality fast turn-around production at the Karolinska Institutet”, says Jens Hjerling-Leffler.
The facility is a collaboration between the two Departments of Medical biochemistry and biophysics and of Cell and Molecular Biology.
Monday September 18th, 2017 09:13:21 PM
Today SveDem is the world's largest quality register for dementia diseases, and in May this year ten years had past since the registry was started. This was celebrated on Thursday, September 14, at the annual meeting of Svenska Läkaresällskapet's premises in Stockholm.
In SveDem, the quality is followed and annually evaluated in the investigation, care and treatment of people who have just received their dementia diagnosis.
"SveDem is a checklist for how the investigation and care will be performed, and one of the few registers that will follow the patient throughout the care chain”, says Maria Eriksdotter, register holder at SveDem and the Head of the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet.
New knowledge about dementia and improved care
Since the commencement of SveDem, all specialist memory clinics and nearly eight out of ten healthcare centers around the country have joined the registry, and data from more than 70,000 people with newly diagnosed dementia disease are included. Access to the information gathered is crucial for developing dementia care, and SveDem has had a major impact on health care.
"The proportion of people undergoing a dementia study that complies with the Swedish Social Board's guidelines has increased dramatically over the past decade, largely due to the fact that we can follow up and provide feedback throughout the care chain”, says Maria Eriksdotter.
The registry has led to many clearly noticeable improvements for patients with dementia. Among other things, since the turn of 2012, there has been a special follow-up for patients with dementia in special housing (the so-called SÄBO module) focusing on nursing measures.
"The interest in the register is also largely notable from an international perspective. Securing this type of registers is very important for strengthening and maintaining Sweden's position as a world leader in this field of research. It helps to improve care and leads to increased knowledge of the patient groups”, says Maria Eriksdotter.
Strong collaboration with academia
Many scientific publications in collaboration between SveDem and NVS have also contributed to this new knowledge over the years, of which several of the publications are listed on SveDem's website.
Monday September 18th, 2017 08:20:01 PM
Starting from this fall, Chenhong Lin is the new chair of the PhD council at the Department of Neurobiology, Care Sciences and Society (NVS).
At the top of the new chair´s agenda is to work closely with the department on common goals, such as increased visibility within and outside of Karolinska Institutet, and to create a welcoming and supporting work environment for the PhD students.
“Many of the goals in the action plans are the same for the department and the council, therefore I would like to align the two in a more structured manner so that the council’s activities also support the goals of NVS in general, this will have a bigger effect compared to if we make a separate plan for the council”, says Chenhong Lin and continues:
“The PhD students make up a big part of the employees at NVS and it is important that we are good ambassadors for the department, and for the research and education that we conduct.”
To support that goal, Chenhong Lin wants to make sure that every PhD student starting at NVS gets the full support needed, and gets to learn about the department and KI.
“We already have a well-established introduction routine working together with the management and administration for doctoral education at NVS, but we can strengthen the parts in which the PhD students gets to learn about their rights and obligations, equal treatment, and also social aspects and how to make new acquaintances”, says the chair.
In her new role, she would also like to continue the great work done by Anna Marseglia, who she is succeeding on the chair post.
“Anna Marseglia did a lot of good things for the PhD students at NVS, and I want to keep up the great initiatives on for example physical and social activities and equal treatment. I´m also very happy to be working on these matters in the great company of the other council members”, says Chenhong Lin.
Monday September 18th, 2017 12:14:02 PM
Professor Emeritus Marc Bygdeman has been awarded The Grand Silver Medal for outstanding contributions to research, education and healthcare and for significant involvement in the World Health Organisation’s work in fertility and family planning.
He has dedicated his entire professional life to developing safer and more effective methods of abortion. During this time he has also worked unstintingly for the introduction and defence of the current abortion legislation. Under Professor Bygdeman’s leadership, research at Karolinska Institutet’s WHO centre has resulted in development of the medically-induced abortion, which today is well-established and is preferred by more than 90 percent of Swedish women as it minimizes the risks compared with surgical intervention.
Every year, about 50,000 women around the world die as the result of unsafe abortions. Effective, safe and accepted abortion methods are essential for reproductive health. Changed abortion methods, which are more accessible, accepted and safe, thus have enormous importance for women’s health.
The Grand Silver Medal 2017 from Karolinska Institutet is awarded to Tore Curstedt and Marc Bygdeman in special recognition of the outstanding contributions they have made to medical research and Karolinska Institutet.
Friday September 15th, 2017 01:51:55 PM
The Infection clinic and the Center for Infection Medicine (CIM) attended the day by inviting a hospital and clinic cross-seminar on sepsis research in Stockholm.
Anna Norrby-Teglund, Professor at Center for Infectious Medicine and Kristoffer Strålin, Infection Clinic, organized the meeting, where several researchers/clinics presented their projects and discussed future activity to continue developing sepsis research.
The meeting was sponsored by the Infection Clinic, Karolinska University Hospital.
Friday September 15th, 2017 12:18:08 PM
This September, KI researcher Shervin Shahnavaz will be participating in two scientific conferences in Ljubljana and Vienna. In order to reduce his and KI’s negative environmental impact, he´s taking the train instead of flying for his official business travels, something he consider to be the responsibility of every KI co-worker who has the opportunity to choose.
Anyone who believe in a scientific attitude also has a responsibility to take research findings seriously and use the knowledge that is developed, according to Shervin Shahnavaz, researcher at the Department of Dental Medicine, who chooses to travel climate-smart for both his private and his business travels.
“In the research community we need to practise what we preach and by our actions show that we take results of climate research seriously. If we don’t change our travel habits for the better, we undermine research and its importance in general,” says Shervin Shahnavaz.
The inspiration to travel by train on his upcoming trips came during March for Science last spring, a manifestation to underline the importance of science and research-based knowledge in society with an emphasis on climate research. But he has had an ambition to reduce his climate footprint in both his private and his business travels for a long time.
“I’ve travelled by train to southern Europe with my family on holiday and discovered that it’s both pleasant and doable. At work, thanks to our head’s and the staff’s openness and interest in environmental issues, we have for several years had an ongoing dialogue about environmentally adapted travel, and when the section was to make a study visit to Denmark we chose to travel by train.”
Means of transport is important but also to plan ahead
Shervin Shahnavaz tries to make all his domestic trips by train and as he says himself, hopefully also many trips in Europe. He is however aware that some international trips cannot be made by train and then advocates being restrictive and where possible cut down on unnecessary business travels.
“Online conferences should be much more common than they are today. I also try to combine several activities during the same trip. In addition to attending the two congresses, this time I’ll also be networking, holding a seminar on children’s and young people’s healthcare together with colleagues from a sister section, and making study visits to colleagues.
The trips to Ljubljana and Vienna will take two weeks, of which about two days will be spent travelling.
Wouldn’t it have been more time-efficient to fly?
“That depends on how we define ‘time-efficient’. Of course it would be faster to fly to southern Europe but that does not automatically mean that you get more out of the trip or that you use your working time more effectively. I’ll spend the night on the train and during the day I’ll be writing a scientific article and preparing my presentations. On my way home I’ll have my colleague Jonas Rafi with me and we’ll be able to have thorough discussions about how we can apply what we’ve learned during the congresses. And then of course I’m going to take the opportunity to look out of the window at the parts of Europe I pass through.”
So what about the price? Shervin Shahnavaz says that on these particular trips, to fly is the more expensive choice.
“The price is important but it’s also important to reduce one’s climate impact. KI’s business trips make up the university’s largest climate impact, with long-distance flights accounting for most of it. It´s therefore important that we as employees and our organisation raise awareness and take action on this issue, it affects us all,” says Shervin Shahnavaz.
Environmental issues given greater prominence in KI’s travel guidelines
International journeys by air are a prerequisite for KI’s activities and operations, but with its updated travel rules KI is encouraging employees to use more environment-friendly means of transport for short journeys, and to arrange travel-free meetings.
The university’s action plan for the environment and sustainable development 2016-2018 also defines a goal of reducing the negative climate impact from KI’s business travel by three percent from the beginning of 2017 to the end of 2018. It is to be achieved by, among other things, educating employees in digital technology for travel-free meetings, favouring eco-labelled hotels and choosing means of transport with the least possible environmental impact.
“In our new rules and instructions for business travels, that came into effect in May, we have taken a holistic approach to our travelling that includes all means of transport. Wherever possible KI’s negative environmental impact is to be reduced, for example by travelling by public transport instead of by taxi or taking the train instead of flying,” says KI’s Travel Manager Kjell-Ove Lindgren.
He also says that we should always ask ourselves what the outcome of a meeting will be if we use modern technology such as video conferencing or webinars instead of travelling.
“If the outcome is the same, choose a travel-free meeting. There are extremely good technical solutions today for holding meetings at a distance so some business trips are totally unnecessary.”
KI´s needs are still the deciding factor
It should however be made clear that KI will not introduce measures that are not appropriate for its operations and activities, Kjell-Ove Lindgren emphasises.
“It is not a question of avoiding all travelling. Physical meetings are needed and cannot always be replaced. The focus is first and foremost on trips that are made across half the country for shorter meetings, and where a video conference might be a better alternative.”
“Not needing to travel also makes our day easier; we don’t need to book transport, check with the family, stay at a hotel and so on. We can work efficiently, leave work on time and have our free time be just that,” Kjell-Ove Lindgren goes on.
To learn from each other, universities in Sweden have started a network group consisting of the Royal Institute of Technology, Umeå University, Lund University, Uppsala University, the Swedish University of Agricultural Sciences, Stockholm University and Linköping University.
“We meet twice a year and exchange experience and discuss how we together can develop the best solutions for our colleagues regarding traveling and environmental impact,” says Kjell-Ove Lindgren.
KI’s policy on business travel and the environment/sustainability
KI’s travel rules state that university employees are to:
• Always consider ways to hold a travel-free meeting
• Take the train instead of flying to Gothenburg and for other short domestic trips
• Choose eco-taxi
• Rent an eco-car
• Use the KI bus to travel between KI campuses
• Use public transport
• Choose hotels that are eco-labelled, eco-certified or that can in some other way prove that they work actively with environmental issues
1 flight = 74,000 travels by train
A person who flies between Stockholm and Gothenburg contribute to the emission of as much carbon dioxide as 74,000 travels by train for the same route would result in.
Text: Selma Wolofsky
Friday September 15th, 2017 09:35:04 AM
For a little over a month, Ole Petter Ottersen has been on his new job as the vice-chancellor of Karolinska Institutet (KI). The time has been used wisely in getting to know the organisation and its employees. However, focus is already on a new KI strategy for 2030 and reorganisation, measures following the Heckscher inquiry and contacts with the Stockholm County Council (SLL), among lots of other things.
How has your first month as KI’s vice-chancellor been?
“It’s been fascinating, with an extremely steep learning curve. I’ve spoken with many KI employees, been to both the Flemingsberg and Solna campuses and met the Stockholm County Council and Karolinska University Hospital – all very important meetings. I have also had talks with all heads of departments.
I’ve formed a very good first impression of KI and I'm impressed by all the research that’s being done here. I also see possibilities for KI to become an even stronger medical university in the future.
Right now, I’m very happy. We’ve just had a first residential meeting with the Board of Karolinska Institutet, and the board strongly supported my idea that KI should institute a collegial council. Through this council, KI employees will be able to put their education and research ideas forward to the management and the board. It's important that all our employees get real influence. However, the decision hasn’t yet been formally taken.”
What has made the greatest impression?
“One of the strongest impressions was left by the meet and mingle with the new students who have come to KI full of expectations and inquisitiveness. Listening to them was very stimulating.”
What has been your primary focus?
“Thus far, getting to know KI’s organisation, listening, asking questions and forming ideas of the major challenges facing KI. Also, seeing all the great opportunities. Balance is important.”
What has been most instructive?
“Walking around the campuses and visiting various departments. I’ll be calling in at all of them in the future. Speaking with Karin Dahlman-Wright and learning about all the great work she and several others have done during the past one and a half very turbulent years, has also been instructive and useful.”
Is there anything that you have already re-evaluated about KI?
“I’ve followed KI throughout my entire career. Now that I see KI from the inside, I realise even more clearly how strong its research is. I can also see the potential for KI to be an even better university as regards to education.”
What is your focus right now?
“On top of the very important visits to the departments, we have been commissioned by the board to review KI’s organisation. The action plan following the Heckscher inquiry must also be seen through. Additionally, we must ensure that all the moving-in processes, for example Biomedicum and Neo, can be carried out optimally.
Hard work is now also starting on KI’s strategy 2030. Such long-term work forces us to think very creatively and to put students and young researchers and their career paths in focus. And, not least, it will be possible to link the strategy to the UN's Agenda 2030 and the global goals for sustainable development. As a world-leading university, KI has an important responsibility to work for sustainable development, and particular in the field of public health.
I also want to put a lot of energy into establishing good relations between KI and SLL and between KI and Karolinska University Hospital. This is perhaps one of the most important things.”
Text: Helena Mayer
Feed aggregation powered by Syndicate Press.
Processed request in 0.78268 seconds.